The first MedChemComm “Accepted Manuscript” is now published. Jacqueline Marchand-Brynaert (Université catholique de Louvain, Belgium) and colleagues’ article is now available to download.
All MedChemComm authors now have the opportunity to have the unedited version of their article published shortly after acceptance, meaning that results are now published, in citable form, even earlier than before. More details…..
This week, the RSC launched a new product, RSC e-membership, allowing anyone to access an electronic version of Chemistry World through a MyRSC account and to enjoy the benefits of electronic networking via this professional online community for £20/year.
Subscribers to this do not benefit from the professional recognition or any of the other many services and discounts available to RSC Members, but it allows chemists from around the world, many already members of another chemical society in their own country, to benefit from the highly-esteemed content in Chemistry World and the networking opportunities offered from MyRSC, which now stands at over 11,000 members. The RSC e-membership also allows subscribers to join a virtual specialist interest group on MyRSC. If you are interested in joining, please visit www.rsc.org/emembership.
MedChemComm has been making the headlines again!
The recently published article by Chris Easton and colleagues at the Australian National University entitled “Potent and selective inhibitors of human peptidylglycine α-amidating monooxygenase” was picked-up by several news outlets, including Medical News Today:
Love Hormone Oxytocin Inspires New Small-cell Lung Cancer Treatment Research
One in Every 28 Australians Are Diagnosed With Lung Cancer, Says Study
Lung cancer breakthrough yields new love hormone insights
Sex gives clues to new lung cancer treatment
Enzyme PAM Linked to Small Cell Lung Cancer: Study
Congratulations to Professor Easton and team!
We are delighted to announce a special themed issue of MedChemComm on Natural Products, due for publication in summer 2012
This themed issue, guest edited by Professor Christopher T. Walsh and Dr Sylvie Garneau-Tsodikova will collect together in one place some of the latest exciting research natural products chemistry, including, but not limited to: biosynthesis, novel natural products as drug or drug leads, novel technologies for natural products discovery, novel chemical transformations in natural product biosynthesis, as well as chemical and chemoenzymatic synthesis of natural products. Authors will benefit from increased exposure of their research alongside similar high level and cutting edge work.
Deadline for Submission: January 31, 2012. Although publication of the issue is scheduled for summer 2012, web publication of the Advance Article versions of each manuscript will proceed as soon as the article is ready, ensuring that research is disseminated without delay.
Manuscripts can be submitted using the online web submissions service at http://mc.manuscriptcentral.com/mcc. Please indicate on submission in the comments to editor section that your manuscript is invited and intended for the Natural Products themed issue.
For more information please contact the Editorial Office.
Take a look at MedChemComm‘s most cited articles so far. As with all of our articles, you can enjoy free access to these for the remainder of 2011:
Chemical space as a source for new drugs
Jean-Louis Reymond, Ruud van Deursen, Lorenz C. Blum and Lars Ruddigkeit
Med. Chem. Commun., 2010, 1, 30-38
Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists
Julia M. Adam, Jim Cairns, Wilson Caulfield, Phillip Cowley, Iain Cumming, Morag Easson, Darren Edwards, Morag Ferguson, Richard Goodwin, Fiona Jeremiah, Takao Kiyoi, Ashvin Mistry, Elizabeth Moir, Richard Morphy, Jason Tierney, Mark York, James Baker, Jean E. Cottney, Andrea K. Houghton, Paul J. Westwood and Glenn Walker
Med. Chem. Commun., 2010, 1, 54-60
Silver nanoparticles—the real “silver bullet” in clinical medicine?
Kenneth K. Y. Wong and Xuelai Liu
Med. Chem. Commun., 2010, 1, 125-131
Cytotoxic sugar analogues of an optimized novobiocin scaffold
Alison C. Donnelly, Huiping Zhao, Bhaskar Reddy Kusuma and Brian S. J. Blagg
Med. Chem. Commun., 2010, 1, 165-170
Photografted poly(methyl methacrylate)-based high performance protein microarray for hepatitis B virus biomarker detection in human serum
Yingshuai Liu, Weihua Hu, Zhisong Lu and Chang Ming Li
Med. Chem. Commun., 2010, 1, 132-135
Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
Hengmiao Cheng, Shubha Bagrodia, Simon Bailey, Martin Edwards, Jacqui Hoffman, Qiyue Hu, Robert Kania, Daniel R. Knighton, Matthew A. Marx, Sacha Ninkovic, Shaoxian Sun and Eric Zhang
Med. Chem. Commun., 2010, 1, 139-144
Effect of particle shape on phagocytosis of CdTe quantum dot–cystine composites
Zhisong Lu, Yan Qiao, Xin Ting Zheng, Mary B. Chan-Park and Chang Ming Li
Med. Chem. Commun., 2010, 1, 84-86
The Royal Society of Chemistry was present in Anaheim for the ACS Spring 2011 National Meeting and Exposition last March. Very hectic few days full of Journal celebrations, product demos and workshops.
We were very happy to hear that one of our MedChemComm authors, Jose Medina Franco, paid the RSC booth a visit.
Here you can see him with a copy of MedChemComm Issue 1, where his article was published.
Thanks to Jose for dropping by! You can now read his article, which is free to access here.
Structure–activity relationships of benzimidazole derivatives as antiparasitic agents: Dual activity-difference (DAD) maps
Jaime Pérez-Villanueva, Radleigh Santos, Alicia Hernández-Campos, Marc A. Giulianotti, Rafael Castillo and Jose L. Medina-Franco
Med. Chem. Commun., 2011, 2, 44-49
DOI: 10.1039/C0MD00159G
If you want to find out where we are going this year and you want to come and meet us, like Jose did, we would love to hear from you. These are the list of conferences we are planning to go to:
Don’t miss out on early bird registration for the RSC’s Residential School in Medicinal Chemistry, being held this year at Burleigh Court Conference Centre at Loughborough University on 4-8 July 2011.
For over 30 years this course has been regarded as the pre-eminent industry training course for medicinal chemists. It brings together cross-industry and cross-discipline practitioners to provide lectures, tutorials, workshops and case-studies illustrating modern drug discovery. This provides an excellent training opportunity for young medicinal chemists. The course also provides a refresher for those who are more experienced but wish to expand their knowledge or offers an introduction to drug design thinking for any scientist working in cross-functional discovery teams. In addition, the opportunity to network with and learn from highly experienced medicinal chemistry professionals is the unique feature of this training school. For the training content and list of course tutors, please see www.rsc.org/medchemtraining
The early bird registration for this event will close on 1st April (although standard registration will remain open until 13th May). Places can be secured quickly and simply via the online booking system. Please note that previous courses have been oversubscribed so please encourage interested parties to register early to be sure of their place!
To find course details, register online and download flyers visit: www.rsc.org/medchemtraining
Welcome to MedChemComm Issue 3!
In this new issue, you’ll find a new collection of exciting papers on medicinal chemistry research, which you can download for free!
This month’s menu includes:
– The importance of solvation in the design of ligands targeting membrane proteins
– Repairing faulty genes by aminoglycosides: Identification of new pharmacophore with enhanced suppression of disease-causing nonsense mutations
– Synthesis and anti HSV-1 evaluation of novel indole-3,4-diones
– Novel indolizine compounds as potent inhibitors of phosphodiesterase IV (PDE4): structure–activity relationship
– The discovery of a novel prototype small molecule TLR7 agonist for the treatment of hepatitis C virus infection
– Synthesis and biological evaluation of novel ferrocenyl curcuminoid derivatives
– Interactions of polysulfanes with components of red blood cells
– Structure-based design, synthesis, and profiling of potent and selective neuronal nitric oxide synthase (nNOS) inhibitors with an amidinothiophene hydroxypiperidine scaffold
– Carba-LNA modified siRNAs targeting HIV-1 TAR region downregulate HIV-1 replication successfully with enhanced potency
That is a great selection, isn’t it? We hope you enjoy it and you find it enlightening.
Israeli scientists have developed compounds that could be better treatments for genetic diseases than current drugs.
Timor Baasov and his colleagues at the Israel Institute of Technology have improved compounds used to suppress faults in genes called nonsense mutations.
Nonsense mutations, which cause more than 1800 human diseases, are alterations in the genetic code that stop protein production prematurely, leading to truncated or nonfunctional proteins. Gene therapy is one treatment, but it’s had limited success. With suppression therapy, small molecules allow cells’ protein producing equipment to skip over nonsense mutations to restore the proteins. Aminoglycosides – antibiotic amine-modified sugars – are the only clinically available drug family known to be effective in suppression therapy, but at effective doses, the compounds have high human toxicity.
Two aminoglycoside derivatives were found to suppress alterations in the genetic code called nonsense mutations
Read the full story in Chemistry World
Link to journal article
Repairing faulty genes by aminoglycosides: Identification of new pharmacophore with enhanced suppression of disease-causing nonsense mutations
Jeyakumar Kandasamy, Dana Atia-Glikin, Valery Belakhov and Timor Baasov,
Med. Chem. Commun., 2011, DOI: 10.1039/c0md00195c
MedChemComm article by Chung Sung-kee and co-workers has been highlighted in The Korea Herald.
A group of South Korean researchers said Monday that they found a way to use drugs to fight brain tumors that are currently treated with only surgery and chemotherapy.
You can read the whole story here and also download the article which is free to access here.
Preparation of blood-brain barrier-permeable paclitaxel-carrier conjugate and its chemotherapeutic activity in the mouse glioblastoma model
Juyoun Jin, Woo Sirl Lee, Kyeung Min Joo, Kaustabh K. Maiti, Goutam Biswas, Wanil Kim, Kyong-Tai Kim, Se Jeong Lee, Kang-Ho Kim, Do-Hyun Nam and Sung-Kee Chung
Med. Chem. Commun., 2011
DOI: 10.1039/C0MD00235F
